Alnylam Assist® Provides Support THROUGHOUT YOUR JOURNEY

Ways to save and learn more about AMVUTTRA® (vutrisiran)

Alnylam Assist® provides services and resources designed to help you navigate your treatment journey. Alnylam Assist® offers support with insurance coverage, financial assistance*, disease and treatment education, and starting AMVUTTRA.

Financial Assistance

Most patients treated with AMVUTTRA pay $0 out-of-pocket†
  • Alnylam Assist® Copay Program‡
    can cover certain out-of-pocket costs for eligible people with commercial insurance.
    • If your doctor submits a Start Form, an Alnylam Case Manager will work with you to determine your eligibility for the Copay Program and enroll you if appropriate
    • You also have the option to enroll yourself in the Alnylam Assist® Copay Program here
  • Other Financial Assistance
    If your HCP has completed a Start Form, an Alnylam Case Manager will determine if you are eligible for other financial assistance
    • Alnylam Assist® Patient Assistance Program (PAP): AMVUTTRA may be provided at no cost to people who meet eligibility criteria
    • If you are experiencing a delay or gap in coverage, there are programs that may be able to help you

SUPPORT TEAM

The Alnylam support team is ready to help you along the treatment journey:
  • Case Managers
    After your doctor submits a Start Form, an Alnylam Case Manager will reach out to you and provide ongoing support, including
    • Starting treatment with AMVUTTRA
    • Understanding and verifying your insurance coverage
    • Determining whether you're eligible for financial assistance
    • Making sure you have continued access to AMVUTTRA
  • Patient Education Liaisons
    Alnylam Patient Education Liaisons (PELs) can provide education and answer questions for you and your family:
    • Provide education to help you better understand ATTR-CM
    • Answer questions about AMVUTTRA
    • PELs are employees of Alnylam Pharmaceuticals. They are not acting as healthcare providers and are not part of your healthcare team
Alnylam Assist logo

Learn more about the services and resources available through Alnylam Assist®

Call 1-833-256-2748 Monday–Friday, 8AM–6PM
Visit AlnylamAssist.com
Download the Alnylam Assist® brochure

*Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue any program at any time.

†Data on file.

‡Patients with Medicare, Medicaid, or other government-sponsored insurance are not eligible for the Alnylam Assist® Copay Program. Out-of-pocket costs for the administration of AMVUTTRA will not be covered for patients residing where it is prohibited by law or where otherwise restricted.

IMPORTANT SAFETY INFORMATION

What are the most important things I should know about AMVUTTRA® (vutrisiran)?

AMVUTTRA can cause low vitamin A levels

Treatment with AMVUTTRA lowers the amount of vitamin A in your blood. Your doctor will tell you to take a vitamin A supplement every day. You should not take more than the amount of vitamin A recommended by your doctor.  

Low vitamin A levels can affect vision. If you have problems with your vision (e.g., night blindness) while taking AMVUTTRA, talk to your doctor. Your doctor may refer you to an eye specialist.

What are the common side effects of AMVUTTRA?

The most common side effects of AMVUTTRA were pain in the arms or legs, pain in the joints, shortness of breath, and low vitamin A levels.

These are not all the possible side effects of AMVUTTRA. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the U.S. Food and Drug Administration (FDA). Visit www.fda.gov/medwatch, or call 1‑800‑FDA‑1088.

For additional information about AMVUTTRA, please see the full Prescribing Information.

Indications

What is AMVUTTRA?

AMVUTTRA is a prescription medicine that treats the:

  • cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR‑CM) in adults to reduce heart-related death, hospital stays and urgent visits.
  • polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR‑PN) in adults.

For additional information about AMVUTTRA, please see the full Prescribing Information.

Footer Waves Left Footer Waves Right